CAR T-Cell Therapy: Changing the Treatment Landscape for Hematologic Malignancies

Download All
In this engaging online program, watch experts discuss emerging strategies and current best practices in CAR T-cell therapy for patients with lymphomas, leukemias, and myelomas. Download slides with all the key data, view the on-demand Webcast, and join the discussion with expert-authored commentaries and podcasts.
Renier J. Brentjens, MD, PhD
Program Director
Jeremy S. Abramson, MD, MMSc
Renier J. Brentjens, MD, PhD
Frederick L. Locke, MD
Noopur Raje, MD

Downloadable Slidesets

Download this short summary slideset of key takeaway points from a live presentation on integrating CAR T-cell therapy into management of patients with hematologic malignancies.

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 18, 2021

Download these slides from our live meeting series to review key strategies for integrating CAR T-cell therapy into your management of patients with hematologic malignancies.

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 11, 2021

ClinicalThought

With the approval of lisocabtagene maraleucel, another CAR T-cell therapy option is now available for patients with relapsed/refractory lymphomas. Review this expert commentary on how to incorporate this agent into your practice.

Jeremy S. Abramson, MD, MMSc Released: March 12, 2021

Podcast

Listen to Noopur Raje, MD, answer audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy.

Noopur Raje, MD Released: March 12, 2021

Download this slideset for key insights from our podcast featuring expert answers to questions on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy.

Noopur Raje, MD Released: March 12, 2021

Listen to Frederick L. Locke, MD, answer audience questions from a live CCO Webinar focused on current best practices and emerging strategies in the use of CAR T-cell therapy for patients with lymphomas.

Frederick L. Locke, MD Released: March 18, 2021

On Demand Webcast

In this interactive on-demand Webcast, expert faculty members discuss how they currently use CAR T-cells to treat hematologic malignancies and provide a look ahead at new data and promising agents that may soon change practice.

Renier J. Brentjens, MD, PhD
Program Director
Frederick L. Locke, MD Noopur Raje, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: March 29, 2021 Expired: March 28, 2022
Provided by Medical College of Wisconsin in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Kite Pharma

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue